DOCSLIB.ORG

White Blood Cell Growth Factors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
White Blood Cell Growth Factors Corporate Medical Policy White Blood Cell Growth Factors File Name: white_blood_cell_growth_factors Origination: 9/2016 Last P&T Review: 6/2021 Next P&T Review: 1/2022 Last Review: 6/2021 Description of Procedure or Service White blood cell growth factors, also known as colony stimulating factors (CSF), are administered to enhance recovery of blood related functions in neutropenia (low white blood count) including febrile neutropenia (FN). CSFs are also utilized to decrease the incidence and severity of infection associated with select disease-related and drug-related myelosuppression (inhibition of bone marrow function). Granulocyte colony stimulating factors (G-CSF) are glycoproteins which exert major control over the reproduction and maturation of certain white blood cells, which include the following U.S. Food & Drug Administration (FDA) approved products: • Filgrastim (Neupogen®, Amgen, Thousand Oaks, CA) • Pegfilgrastim (Neulasta® and Neulasta® OnPro®, Amgen, Thousand Oaks, CA) • Pegfilgrastim-apgf (Nyvepria™, Pfizer, Lake Forest, IL) • Pegfilgrastim-bmez (Ziextenzo™, Sandoz, Princeton, NJ) • Pegfilgrastim-cbqv (Udenyca™, Coherus BioSciences, Redwood City, CA) • Pegfilgrastim-jmdb (Fulphila™, Mylan, Rockford, IL) • Filgrastim-aafi (Nivestym™, Pfizer, Lake Forest, IL) • Filgrastim-sndz (Zarxio®, Sandoz, Princeton, NJ) • Tbo-filgrastim (Granix®, Sicor Biotech UAB/Teva Pharmaceuticals, North Wales, PA) Granulocyte-macrophage colony stimulating factor (GM-CSF) is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. • Sargramostim (Leukine®, Bayer Healthcare Pharmaceuticals, Seattle, WA) ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for White Blood Cell Growth Factors when it is determined to be medically necessary because the medical criteria and guidelines shown below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. Page 1 of 10 An Independent Licensee of the Blue Cross and Blue Shield Association When White Blood Cell Growth Factors are covered For all indications, Pegfilgrastim (Neulasta, Neulasta OnPro), Pegfilgrastim-apgf (Nyvepria), Pegfilgrastim-bmez (Ziextenzo), Pegfilgrastim-cbqv (Udenyca), Pegfilgrastim-jmdb (Fulphila), Filgrastim (Neupogen), Filgrastim-aafi (Nivestym), Filgrastim-sndz (Zarxio), Tbo-filgrastim (Granix), and Sargramostim (Leukine) are considered medically necessary if the following criteria are met: 1. The request is for Neulasta, Neulasta OnPro, Fulphila, Nyvepria, Udenyca, or Ziextenzo; AND a. If the request is for Neulasta (pegfilgrastim) or non-preferred pegfilgrastim biosimilars [e.g., Fulphila (pegfilgrastim-jmdb), Nyvepria (pegfilgrastim-apgf)], then both of the following criteria are met: i. The patient has a documented serious adverse event that required medical intervention to both preferred biosimilar pegfilgrastim products [i.e., Udenyca (pegfilgrastim-cbqv), Ziextenzo (pegfilgrastim- bmez)] that is not anticipated with the requested product; AND ii. The prescriber has completed and submitted an FDA MedWatch Adverse Event Reporting Form (the prescriber must provide a copy of the completed MedWatch form. Authorizations will not be considered unless the form is completed and submitted to the FDA); AND b. If the request is for Neulasta OnPro, the patient has an inability to physically or cognitively adhere to the treatment schedule including all of the following: i. Inability to self-administer the medication; AND ii. Lack of caregiver or support system for assistance with medication administration; OR 2. The request is for Granix, Neupogen, Nivestym, or Zarxio; AND a. If the request is for Neupogen (filgrastim) or non-preferred filgrastim biosimilars [e.g., Granix (tbo-filgrastim)], then both of the following criteria are met: i. The patient has a documented serious adverse event that required medical intervention to both preferred biosimilar filgrastim products [i.e., Nivestym (filgrastim-aafi), Zarxio (filgrastim-sndz)] that is not anticipated with the requested product; AND ii. The prescriber has completed and submitted an FDA MedWatch Adverse Event Reporting Form (the prescriber must provide a copy of the completed MedWatch form. Authorizations will not be considered unless the form is completed and submitted to the FDA); AND Primary Prophylaxis of febrile neutropenia One white blood cell (WBC) growth factor agent is considered clinically appropriate for primary prophylaxis of chemotherapy-induced febrile neutropenia when ALL of the following (1,2, and 3 are met: 1. The individual has a non-myeloid malignancy and is NOT receiving chemotherapy with radiation concurrently; 2. Chemotherapy intent must include ONE of the following: a. Curative intent, such as adjuvant treatment for early stage disease ; OR b. Intent is survival prolongation, and the use of a different regimen or dose reduction would reduce the likelihood of reaching the treatment goal; OR c. Intent is symptom management, and the use of a different regimen or dose reduction would reduce the likelihood of reaching the treatment goal. 3. The individual falls into one of the following risk categories for febrile neutropenia: a. High risk of febrile neutropenia (> 20%) based on chemotherapy regimen; OR b. Intermediate risk of febrile neutropenia (> 10% but < 20 %) based on chemotherapy regimen and at least ONE of the following significant risk factors: • Age > 65; • Poor performance status (ECOG 3 or 4, but chemotherapy still indicated); Page 2 of 10 An Independent Licensee of the Blue Cross and Blue Shield Association • Preexisting neutropenia, for example resulting from bone marrow damage or tumor infiltration (ANC < 1500 mm3 ); • Previous febrile neutropenia episode; • Bone marrow infiltration by tumor; • Liver dysfunction, with bilirubin > 1.0 or liver enzymes > 2x upper limit of normal; • Presence of open wounds or active infections, when chemotherapy cannot be delayed to accommodate recovery; • Renal dysfunction, with creatinine clearance less than 50 ml/min; • Poor nutritional status (baseline albumin less 3.5 g/dl or BMI < 20); • HIV infection (active); • Advanced cancer Secondary Prophylaxis of febrile neutropenia Secondary prophylaxis of febrile neutropenia is considered clinically appropriate when there has been a previous neutropenic complication (in the absence of primary prophylaxis), and a change to the regimen (including dose reduction, schedule change, or change in therapy) would be expected to compromise patient outcome, particularly in the setting of curative intent. Adjunctive treatment of febrile neutropenia (primary prophylaxis not given) Adjunctive treatment of febrile neutropenia is considered clinically appropriate when any of the following risk factors are present: • Age > 65 • Neutrophil recovery is expected to be delayed (greater than 10 days) • Neutropenia is profound (less than 0.1 x 109) • Active pneumonia • Sepsis syndrome (hypotension and/or multi-organ damage/dysfunction noted) • Invasive fungal or opportunistic infection • Onset of fever during inpatient stay Note: Febrile neutropenia is defined as an oral temperature > 38.3°C (101.0°F) or 2 consecutive readings of 38.0°C (100.4°F) for 1 hour, with an absolute neutrophil count less than 500 cells/microL (0.5 x 109/L) or less than 1000 cells/microL and expected to fall below 500 cells/microL over the next 48 hours. Other oncologic uses for WBC growth factors The following indications by growth factor type are also considered clinically appropriate when the requirements below are met: Filgrastim/filgrastim-aafi/filgrastim-sndz/Tbo-filgrastim 1. Acute lymphocytic leukemia a. After start of induction or first post-remission chemotherapy course; OR b. As an alternate or adjunct to donor leukocyte infusions (DLI) for relapsed disease after transplant. 2. Acute myeloid leukemia a. After induction, reinduction, or consolidation; OR b. As an alternate or adjunct to donor leukocyte infusions (DLI) for relapsed disease after transplant. 3. Aplastic anemia, moderate or severe 4. Hairy cell leukemia a. To treat severe neutropenia 5. Hematopoietic stem cell transplant a. To promote bone marrow myeloid recovery; OR b. To treat delayed or failed engraftment; OR c. To mobilize stem cells for collection by pheresis Page 3 of 10 An Independent Licensee of the Blue Cross and Blue Shield Association 6. Myelodysplastic syndrome a. To treat recurrent infection; OR b. To treat neutrophil count < 500 mm3 7. Radiation exposure a. Following radiation therapy in the absence of chemotherapy, if prolonged delays are expected; OR b. After accidental or intentional body irradiation of doses greater than 2 Gy (hematopoietic syndrome of acute radiation syndrome). 8. Support for dose dense or dose intensive chemotherapy in any of the following scenarios: a. Adjuvant treatment of high-risk breast cancer with combination therapy that includes anthracycline (doxorubicin or epirubicin)/cyclophosphamide followed by paclitaxel; OR b. High-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (HD-M- VAC) in urothelial cancer; OR c. Chemotherapy
Load more

Recommended publications
  • Infection Control for Neutropenic Cancer Patients : the Libraryuse of Prophylactic Antibiotics Lecture Author Jean A
    Infection control for neutropenic cancer patients : the Libraryuse of prophylactic antibiotics Lecture author Jean A. Klastersky Onlineby Institut Jules Bordet,© Université Libre de Bruxelles (ULB) Brussels, Belgium ESCMID Complications and mortality associated with febrile neutropenia Library No Bacteremia Bacteremia Total ComplicationsLectureDeaths Total Complications Deaths author Solid tumors 784 60 (8 %) 25 135 30 (22 %) 17 Onlineby (3 %) (13 % ) © Hematological cancer 859 111 (13 %) 32 364 76 (21 %) 32 (4 %) (9 %) ESCMID J. Klastersky et al., 2007 2 Complications associated with febrile neutropenia Library Hypotension : systolic blood pressure less than 90 mmHg or need for pressor support to maintain blood pressure Respiratory failure : arterial oxygen pressure less than 60mmHg while breathing room air or needLecture for mechanical ventilation Disseminated intravascular coagulation Confusion or altered mental state author Congestive cardiac failure seen on chest X-ray and requiring treatment Onlineby Bleeding severe enough to require© transfusion Arrhythmia or ECG changes requiring treatment Renal failure requiring investigation and/or treatment with IV fluids, dialysis, or any other intervention ESCMID J. Klastersky et al., 2000 3 Cost of febrile neutropenia Library Initial hospitalization Initial hospitalization plus all downstreamLecture neutropenia care author 2.010 $ Onlineby 14.407 $ © ESCMID D. Weyckler et al., 2008 4 Use of oral antibiotics in protected units environment : clinical effectiveness and role in the emergence
    [Show full text]
  • White Blood Cells and Severe COVID-19: a Mendelian Randomization Study
    Journal of Personalized Medicine Article White Blood Cells and Severe COVID-19: A Mendelian Randomization Study Yitang Sun 1 , Jingqi Zhou 1,2 and Kaixiong Ye 1,3,* 1 Department of Genetics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA 30602, USA; [email protected] (Y.S.); [email protected] (J.Z.) 2 School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China 3 Institute of Bioinformatics, University of Georgia, Athens, GA 30602, USA * Correspondence: [email protected]; Tel.: +1-706-542-5898; Fax: +1-706-542-3910 Abstract: Increasing evidence shows that white blood cells are associated with the risk of coronavirus disease 2019 (COVID-19), but the direction and causality of this association are not clear. To evaluate the causal associations between various white blood cell traits and the COVID-19 susceptibility and severity, we conducted two-sample bidirectional Mendelian Randomization (MR) analyses with summary statistics from the largest and most recent genome-wide association studies. Our MR results indicated causal protective effects of higher basophil count, basophil percentage of white blood cells, and myeloid white blood cell count on severe COVID-19, with odds ratios (OR) per standard deviation increment of 0.75 (95% CI: 0.60–0.95), 0.70 (95% CI: 0.54–0.92), and 0.85 (95% CI: 0.73–0.98), respectively. Neither COVID-19 severity nor susceptibility was associated with white blood cell traits in our reverse MR results. Genetically predicted high basophil count, basophil percentage of white blood cells, and myeloid white blood cell count are associated with a lower risk of developing severe COVID-19.
    [Show full text]
  • WHITE BLOOD CELLS Formation Function ~ TEST YOURSELF
    Chapter 9 Blood, Lymph, and Immunity 231 WHITE BLOOD CELLS All white blood cells develop in the bone marrow except Any nucleated cell normally found in blood is a white blood for some lymphocytes (they start out in bone marrow but cell. White blood cells are also known as WBCs or leukocytes. develop elsewhere). At the beginning of leukopoiesis all the When white blood cells accumulate in one place, they grossly immature white blood cells look alike even though they're appear white or cream-colored. For example, pus is an accu- already committed to a specific cell line. It's not until the mulation of white blood cells. Mature white blood cells are cells start developing some of their unique characteristics larger than mature red blood cells. that we can tell them apart. There are five types of white blood cells. They are neu- Function trophils, eosinophils, basophils, monocytes and lymphocytes (Table 9-2). The function of all white blood cells is to provide a defense White blood cells can be classified in three different ways: for the body against foreign invaders. Each type of white 1. Type of defense function blood cell has its own unique role in this defense. If all the • Phagocytosis: neutrophils, eosinophils, basophils, mono- white blood cells are functioning properly, an animal has a cytes good chance of remaining healthy. Individual white blood • Antibody production and cellular immunity: lympho- cell functions will be discussed with each cell type (see cytes Table 9-2). 2. Shape of nucleus In providing defense against foreign invaders, the white • Polymorphonuclear (multilobed, segmented nucleus): blood cells do their jobs primarily out in the tissues.
    [Show full text]
  • Neutropenia Fact Sheet
    Neutropenia in Barth Syndrome i ii (Chronic, Cyclic or Intermittent) What problems can Neutropenia cause? Neutrophils are the main white blood cell for fighting or preventing bacterial or fungal infections. They may be referred to as polymorphonuclear cells (polys or PMNs), white cells with segmented nuclei (segs), or neutrophils in the complete blood cell count (CBC) report. Immature neutrophils are referred to as bands. When someone is neutropenic (an abnormally low level of neutrophils in the blood), the risk of infection increases. The absolute neutrophil count (ANC) is a measure of the total number of neutrophils present in the blood. When the ANC is less than 1,000, the risk of infection increases. Most infections occur in the ears, skin or throat and to a lesser extent, the chest. These infections can be very serious and may require antibiotics to clear infections. When someone with Barth syndrome is neutropenic his defenses are weakened, he is likely to become seriously ill more quickly than someone with a normal neutrophil count. Tips: • No rectal temperatures as any break in the skin can lead to an infection. • If the individual has a temperature > 100.4° F (38° C) or has infectious symptoms, the primary physician or hematologist should be notified. The individual may need to be seen. • If the individual has a temperature of 100.4° F (38° C) – 100.5° F (38.05° C)> 8 hours or a temperature > 101.5° F (38.61° C), an immediate examination by the physician is warranted. Some or all of the following studies may be ordered: CBC with differential and ANC Urinalysis Blood, urine, and other appropriate cultures C-Reactive Protein Echocardiogram if warranted • The physician may suggest antibiotics (and G-CSF if the ANC is low) for common infections such as otitis media, stomatitis.
    [Show full text]
  • Therapeutic Class Overview Colony Stimulating Factors
    Therapeutic Class Overview Colony Stimulating Factors Therapeutic Class Overview/Summary: This review will focus on the granulocyte colony stimulating factors (G-CSFs) and granulocyte- macrophage colony stimulating factors (GM-CSFs).1-5 Colony-stimulating factors (CSFs) fall under the naturally occurring glycoprotein cytokines, one of the main groups of immunomodulators.6 In general, these proteins are vital to the proliferation and differentiation of hematopoietic progenitor cells.6-8 The G- CSFs commercially available in the United States include pegfilgrastim (Neulasta®), filgrastim (Neupogen®), filgrastim-sndz (Zarxio®), and tbo-filgrastim (Granix®). While filgrastim-sndz and tbo- filgrastim are the same recombinant human G-CSF as filgrastim, only filgrastim-sndz is considered a biosimilar drug as it was approved through the biosimilar pathway. At the time tbo-filgrastim was approved, a regulatory pathway for biosimilar drugs had not yet been established in the United States and tbo-filgrastim was filed under its own Biologic License Application.9 Only one GM-CSF is currently available, sargramostim (Leukine). These agents are Food and Drug Administration (FDA)-approved for a variety of conditions relating to neutropenia or for the collection of hematopoietic progenitor cells for collection by leukapheresis.1-5 Due to the pathway taken, tbo-filgrastim does not share all of the same indications as filgrastim and these two products are not interchangeable. It is important to note that although filgrastim-sndz is a biosimilar product, and it was approved with all the same indications as filgrastim at the time, filgrastim has since received FDA-approval for an additional indication that filgrastim-sndz does not have, to increase survival in patients with acute exposure to myelosuppressive doses of radiation.1-3A complete list of indications for each agent can be found in Table 1.
    [Show full text]
  • Bloodstream Infections in Febrile Neutropenic Patients at a Tertiary Care Center in Lebanon: a View of the Past Decade
    International Journal of Infectious Diseases (2007) 11, 450—453 http://intl.elsevierhealth.com/journals/ijid Bloodstream infections in febrile neutropenic patients at a tertiary care center in Lebanon: a view of the past decade Zeina A. Kanafani a, Ghenwa K. Dakdouki b, Khalil I. El-Chammas c, Shaker Eid d, George F. Araj e, Souha S. Kanj f,* a Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA b Hammoud Hospital, Sidon, Lebanon c Department of Pediatrics, American University of Beirut Medical Center, Beirut, Lebanon d Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon e Department of Pathology & Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon f Division of Infectious Diseases, American University of Beirut Medical Center, Cairo Street, PO Box 113-6044, Hamra 110 32090, Beirut, Lebanon Received 10 October 2006; accepted 11 December 2006 Corresponding Editor: William Cameron, Ottawa, Canada KEYWORDS Summary Neutropenic fever; Objectives: Previous studies from Lebanon have shown Gram-negative organisms to be the Bacteremia; predominant agents in febrile neutropenic patients. The objective of this study was to evaluate Gram-negative infection; the most current epidemiological trends among patients with neutropenic fever. Lebanon Methods: This prospective observational cohort study, the largest to date in the country, was conducted at the American University of Beirut Medical Center between January 2001 and December 2003, with the objective of describing the characteristics of patients with neutropenic fever and to assess temporal trends. Results: We included 177 episodes of neutropenic fever. The most common underlying malignancy was lymphoma (42.4%). Gastrointestinal and abdominal infections were predominant (31.6%) and 23.7% of cases represented fever of unknown origin.
    [Show full text]
  • FULPHILA Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULPHILA safely and effectively. See full prescribing information for -----------------------WARNINGS AND PRECAUTIONS----------------------­ FULPHILA. • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. (5.1) ™ FULPHILA (pegfilgrastim-jmdb) injection, for subcutaneous use • Acute respiratory distress syndrome (ARDS): Evaluate patients who Initial U.S. Approval: 2018 develop fever, lung infiltrates, or respiratory distress. Discontinue ™ ® Fulphila in patients with ARDS. (5.2) FULPHILA (pegfilgrastim-jmdb) is biosimilar* to NEULASTA • Serious allergic reactions, including anaphylaxis: Permanently (pegfilgrastim). (1) discontinue Fulphila in patients with serious allergic reactions. (5.3) • Fatal sickle cell crises: Have occurred. (5.4) ----------------------------INDICATIONS AND USAGE--------------------------- • Glomerulonephritis: Evaluate and consider dose-reduction or Fulphila is a leukocyte growth factor indicated to interruption of Fulphila if causality is likely. (5.5) • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving ------------------------------ADVERSE REACTIONS------------------------------ myelosuppressive anti-cancer drugs associated with a clinically Most common adverse reactions (≥ 5% difference in incidence compared to significant incidence of febrile neutropenia.
    [Show full text]
  • Sargramostim (Leukine®)
    Policy Medical Policy Manual Approved Revision: Do Not Implement until 8/31/21 Sargramostim (Leukine®) NDC CODE(S) 71837-5843-XX LEUKINE 250MCG Solution Reconstituted (PARTNER THERAPEUTICS) DESCRIPTION Sargramostim is a recombinant human granulocyte-macrophage colony stimulating factor (rGM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. Like endogenous GM-CSF, rGM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells in the granulocyte-macrophage pathways which include neutrophils, monocytes/macrophages and myeloid-derived dendritic cells. It is also capable of activating mature granulocytes and macrophages. Various cellular responses such as division, maturation and activation are induced by GM-CSF binding to specific receptors expressed on the cell surface of target cells. POLICY Sargramostim for the treatment of the following is considered medically necessary: o Acute myelogenous leukemia following induction or consolidation chemotherapy o Bone Marrow Transplantation (BMT) failure or Engraftment Delay o Individuals acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome [H-ARS]) o Myeloid reconstitution after autologous or allogeneic bone marrow transplant (BMT) o Peripheral Blood Progenitor Cell (PBPC) mobilization and transplant Sargramostim for the treatment of chemotherapy-induced febrile neutropenia is considered medically necessary if the medical appropriateness
    [Show full text]
  • Vancomycin-Resistant Enterococci Colonization in Patients with Hematological Malignancies: Screening and Its Cost-Effectiveness
    Vancomycin-resistant enterococci colonization in patients with hematological malignancies: screening and its cost-effectiveness Gedik Habip1, Şimşek Funda1, Kantürk Arzu1, Yıldırmak Taner1, Arıca Deniz2, Aydın Demet2, Yokuş Osman2, Demirel Naciye2 1. Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydanı Training and Research Hospital, Istanbul 2. Department of Hematology, Ministry of Health Okmeydanı Training and Research Hospital, Istanbul Abstract: Background and objective: We evaluated the rates of vancomycin-resistant enterococci (VRE) colonization and VRE- related bacteremia in patients with hematological malignancies in terms of routine screening culture and its cost-effective- ness. Materials and Methods: All patients of the hematology department who were older than 14 years of age and who devel- oped at least one febrile neutropenia episode during chemotherapy for hematological cancers between November 2010 and November 2012 were evaluated retrospectively. Results: We retrospectively analyzed 282 febrile episodes in 126 neutropenic patients during a two-year study period. The study included 65 cases in the first study-year and 78 cases in the second study-year. The numbers of colonization days and colonized patient were748 days of colonization in 29 patients (44%) in the first study-year and 547 colonization days in 21 patients (26%) in the second study-year, respectively. Routine screening culture for VRE cost $4516,4 (427 cultures) in the first study-year, $5082,7 (504 cultures) in the second study-year depending on the number of patients and their length of stay. Conclusion: In line with our study results, routine screening of hematological patients for VRE colonization is not cost- effective. Routine surveillance culture for VRE should be considered with respect to the conditions of health care setting.
    [Show full text]
  • Stem Cell Or Bone Marrow Transplant
    cancer.org | 1.800.227.2345 Stem Cell or Bone Marrow Transplant A stem cell transplant, also called a bone marrow transplant, can be used to treat certain types of cancer. This procedure might be called peripheral stem cell transplant or cord blood transplant, depending on where the stem cells come from. Here we’ll explain stem cells and stem cell transplant, cover some of the issues that come with transplants, and describe what it's like to donate stem cells. ● How Stem Cell and Bone Marrow Transplants Are Used to Treat Cancer ● Types of Stem Cell and Bone Marrow Transplants ● Donating Stem Cells and Bone Marrow ● Getting a Stem Cell or Bone Marrow Transplant ● Stem Cell or Bone Marrow Transplant Side Effects How Stem Cell and Bone Marrow Transplants Are Used to Treat Cancer What are stem cells? All of the blood cells in your body - white blood cells, red blood cells, and platelets - start out as young (immature) cells called hematopoietic stem cells. Hematopoietic means blood-forming. These are very young cells that are not fully developed. Even though they start out the same, these stem cells can mature into any type of blood cell, depending on what the body needs when each stem cell is developing. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Stem cells mostly live in the bone marrow (the spongy center of certain bones). This is where they divide to make new blood cells. Once blood cells mature, they leave the bone marrow and enter the bloodstream. A small number of the immature stem cells also get into the bloodstream.
    [Show full text]
  • Automatic White Blood Cell Measuring Aid for Medical Diagnosis
    Automatic White Blood Cell Measuring Aid for Medical Diagnosis Pramit Ghosh, Debotosh Bhattacharjee, Mita Nasipuri and Dipak Kumar Basu Abstract— Blood related invasive pathological investigations increases. It turns into a vicious cycle. On the other hand, a play a major role in diagnosis of diseases. But in India and low count of white blood cells indicates viral infections, low other third world countries there are no enough pathological immunity and bone marrow failure [3]. A severely low white infrastructures for medical diagnosis. Moreover, most of the blood count that is the count of less than 2500 cells per remote places of those countries have neither pathologists nor micro-litre is a cause for a critical alert and possesses a high physicians. Telemedicine partially solves the lack of physicians. But the pathological investigation infrastructure can’t be risk of sepsis [4]. integrated with the telemedicine technology. The objective of In conventional procedure, glass slides containing blood this work is to automate the blood related pathological samples are dipped into Lisman solution before placing it investigation process. Detection of different white blood cells into microscope [5]. Microscope enlarges the pictures of has been automated in this work. This system can be deployed blood samples for manual detection of different white blood in the remote area as a supporting aid for telemedicine technology and only high school education is sufficient to cells; but this manual process totally depends on pathologist. operate it. The proposed system achieved 97.33% accuracy for Some auto cell counting units exist like Cellometer [15], the samples collected to test this system.
    [Show full text]
  • Comparison Between Filgrastim and Lenograstim Plus Chemotherapy For
    Bone Marrow Transplantation (2010) 45, 277–281 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10 $32.00 www.nature.com/bmt ORIGINAL ARTICLE Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs R Ria, T Gasparre, G Mangialardi, A Bruno, G Iodice, A Vacca and F Dammacco Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy Recombinant human (rHu) G-CSF has been widely used during transplantation.4 However, the use of G-CSF after to treat neutropenia and mobilize PBPCs for their autologous PBPC transplantation has been queried, as its autologous and allogeneic transplantation. It shortens further reduction in time to a safe neutrophil count5,6 does neutropenia and thus reduces the frequency of neutropenic not always imply fewer significant clinical events, such as fever. We compared the efficiency of glycosylated rHu infections, length of hospitalization, extrahematological and non-glycosylated Hu G-CSF in mobilizing hemato- toxicities or mortality.7,8 Even so, the ASCO guidelines still poietic progenitor cells (HPCs). In total, 86 patients were recommend the use of growth factors after autologous consecutively enrolled for mobilization with CY plus either PBPC transplantation.9 glycosylated or non-glycosylated G-CSF, and under- G-CSF induces the proliferation and differentiation of went leukapheresis. The HPC content of each collection, myeloid precursor cells, and also provides a functional toxicity, days of leukapheresis needed to reach the activity that influences chemotaxis, respiratory burst and minimum HPC target and days to recover WBC (X500 Ag expression of neutrophils.
    [Show full text]